Administration of a low IGF-1 dose inhibits the somatotroph response to GH-releasing hormone in obese and normal subjects, indicating that somatotroph sensitivity to the inhibitory effect of IGF-1 is conserved in obesity [39]. This evidence concerns the gene IGF1 and obesity disorder.